论文部分内容阅读
目的通过临床实验观察采用胸痹通胶囊联合常规西药治疗慢性心力衰竭病人的临床疗效,评价胸痹通胶囊对慢性心力衰竭的治疗效果。方法选择慢性心力衰竭患者60例,将其随机分为实验组和对照组,每组30例。实验组予以胸痹通胶囊口服,并予以常规西药配合治疗。对照组30例,只进行常规西药治疗。疗程均为30d,观察并记录治疗前后两组患者血清N末端脑钠肽前体(NT-ProBNP)及肌钙蛋白Ⅰ(CTnⅠ)的浓度变化。结果实验组能够显著降低血清NT-ProBNP及CTnⅠ含量,其疗效与对照组比较,差异有显著性(P<0.05)。结论胸痹通胶囊能够显著降低血清中NT-ProBNP和CTnⅠ水平,并显著提高治疗效果。
Objective To observe the clinical efficacy of Chebi Capsule combined with conventional western medicine in the treatment of patients with chronic heart failure through clinical trials and to evaluate the therapeutic effect of Chebi Tablet on chronic heart failure. Methods Sixty patients with chronic heart failure were selected and randomly divided into experimental group and control group, with 30 cases in each group. The experimental group was given Chebi Capsule orally, and to be treated with conventional western medicine. Control group, 30 cases, only conventional western medicine. The course of treatment was 30 days. The changes of serum N-terminal pro-brain natriuretic peptide (NT-ProBNP) and troponin I (CTnⅠ) concentrations in both groups before and after treatment were observed and recorded. Results The experimental group can significantly reduce the serum NT-ProBNP and CTn Ⅰ content, the efficacy compared with the control group, the difference was significant (P <0.05). Conclusion Chebi Capsule can significantly reduce serum NT-ProBNP and CTn Ⅰ levels, and significantly improve the therapeutic effect.